Management
Management
CEO
Michael Scholl
Michael is CEO and Co-Founder of Leukocare, heading strategy, finance, corporate law, marketing & sales and HR. Before joining Leukocare, Michael was an entrepreneur and investor and founded several technology companies. He started his career as business consultant at BCG. Michael holds a master’s degree in business engineering from the University of Berlin.
COO
Dr. Andreas Seidl
Andreas is COO of Leukocare, heading R&D, IP, quality management and Bioinformatics. Andreas has about 20 years experience in analytical and pharmaceutical development of biologics and contributed to the development and approval of many biosimilar products and NBEs. Before joining Leukocare, Andreas held different positions with growing responsibility at Hexal AG, Sandoz Biopharmaceuticals and Novartis. Andreas is a chemist by training with a master’s degree from the University of Constance/Germany and received his Ph.D. in the area of protein analysis and mass spectrometry from the University of Constance.
Dr. Sabine Hauck
VP, Head of R&D
Sabine brings 20 years of Drug Product development expertise as well as several years of in vitro diagnostic and biosensor development to Leukocare. Before joining Leukocare, Sabine was heading Pharmaceutical Development, QA and RA departments (Medigene, Acino, IDEA). She holds a Dr. rer. nat. from University of Regensburg.
Dr. Georg Dönges
VP, Head of Finance
Georg has spent more than 10 years in leading positions in the biotech industry & capital markets. He held various positions in a large finance org., eg. lead for restructuring of Corp. Finance at GfK SE, a KKR portfolio company. Previously, Georg worked at the Max-Planck-Institute of Biochemistry for his PhD thesis and earned the degree of a Certified International Investment Analyst (CIIA).
Dr. Andreas Geissler
VP, Head of IP
Andreas has been counseling pharmaceutical biotech companies on IP strategy for more than 15 years. He is a European and German Patent Attorney. Before joining Leukocare, Andreas served as Head of IP (Medigene) and attorney in private practice. He has in depth experience in IP strategy, portfolio management, patent prosecution, and FTO analysis. He holds a PhD in Molecular Cell Biology from Albert-Ludwigs-University Freiburg.